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Abstract
Background: We reported that in our previous study that wearing intermittent occlusion therapy glasses (IO-
therapy) for 4 hours (h) was non-inferior to patching for 2 h in 3 to 8-year-old children with amblyopia. We
hypothesize that an intense regimen of 12-h IO-therapy per day for 4 weeks could be as effective as the standard
regimen of 4-h IO-therapy per day for 12 weeks in treating moderate amblyopia in 3 to 8-year-old children.
Methods/Design: A total of 56 children between 3 and 8 years of age with amblyopia in association with
anisometropia and/or strabismus will be enrolled. All participants will be prescribed IO-therapy glasses (Amblyz™),
set at 30-s opaque/transparent intervals (i.e., occluded 50% of wear time). They will be randomized to receive the
standard regimen for 12 weeks or the intense regimen for 4 weeks. Adherence to using the IO-therapy glasses will
be objectively monitored in each participant by means of a microsensor dose monitor. The primary study objective
is to compare the effectiveness of an intense regimen to a standard regimen of IO-therapy in 3 to 8-year-old
children with moderate amblyopia. The secondary study objectives are to determine whether adherence differs
between an intense regimen and a standard regimen of IO-therapy, and to determine the dose-response
relationship of IO-therapy.
Discussion: In addition to testing the effectiveness, this study will test for the first time the association between
treatment adherence and the visual outcome of IO-therapy, which will enhance our understanding of the dose-
response relationship of IO-therapy. If an intense regimen is shown to be effective, it would alter amblyopia
treatment strategies and improve visual outcomes.
Trial registration: ClinicalTrials.gov: NCT02767856. Registered on 10 May 2016.
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Background
Amblyopia, affecting 2–4% of all children, is the most
common cause of monocular visual impairment in chil-
dren [1, 2]. Traditional amblyopia treatment consists of
penalization of the better eye using atropine drops or oc-
clusion with an adhesive eye patch, which forces the am-
blyopic eye to have increased visual experience, while
the stronger, fellow eye is pharmacologically blurred
or occluded. In the USA, the current evidence-based
recommendation is to prescribe 2 hours (h) of patching
per day for moderate strabismic or anisometropic am-
blyopia [3–6]. The treatment may last from a couple of
months up to years. Unfortunately, 20–25% of children
do not respond to this patching treatment at all and 40%
of children cannot achieve normal visual acuity [5]. Pos-
sible reasons include poor compliance, older age at start
of treatment, insufficiently intense treatment regimen, or
subclinical anatomicla or functional pathology [7].
Therefore, we continue to search for an alternative,
child-friendly amblyopia treatment and protocol.
Recently, intermittent occlusion therapy (IO-therapy)
with novel glasses utilizing liquid-crystal technology has
presented an interesting alternative to existing treatment
strategies [8–10]. Avoiding the use of adhesive patches,
these IO-therapy glasses can be programmed to unilat-
erally alternate between opaque and transparent phases
at 30-s intervals providing effective occlusion of the fel-
low eye 50% of the time they are worn. For example, the
daily cumulative occlusion dose for 4 h of wearing IO-
therapy glasses equals the occlusion dose for 2 h of
patching. In addition, the optical correction can be in-
corporated into the IO-therapy glasses, which renders
the occlusion less noticeable. Therefore, compared with
adhesive patches, IO-therapy is more child-friendly [11].
We concluded from our previous study that the effect-
iveness of 4-h of wearing IO-therapy glasses with 50%
occlusion is non-inferior to that of 2-h patching in 3–8-
year-old children with amblyopia. Furthermore, the
study supported the hypothesis that the cumulative
amount of occlusion time is critical for the effectiveness
of occlusion treatment in amblyopia; most of the chil-
dren achieving their best visual acuity with a cumulative
dose of 150–250 h [12].
If the cumulative amount of occlusion time is critical
in occlusion treatment, it is reasonable to postulate that
an intense regimen of IO-therapy may achieve faster vi-
sion improvement than is achievable with the standard
regimen: Switching to a more intense regimen has been
reported to be more effective in children with residual
amblyopia, e.g., when the amblyopic eye stopped im-
proving despite 2 h per day of the standard patching
regimen, increasing the patching dosage to 6 h per day
(three times the standard regimen dosage) resulted in
further improvement compared with continuing the
regimen for 2 h per day [13]. Moreover the adherence to
patching decreases with treatment duration [14]. We re-
cently found that adherence with IO-therapy also de-
creases with time [15]. An intense regimen with a faster
outcome may improve adherence. When the child wears
the glasses full time, it may require less effort from the
parent to keep reminding the child to wear the device.
Therefore, it is expected that such an intense regimen
may improve adherence and lead to a better response to
therapy.
To examine a comparison of the IO-therapy regimens,
it is critical to monitor adherence objectively. Unfortu-
nately, previous studies did not measure objective adher-
ence using these IO-therapy glasses, limiting reliable
assessment of the dose-response relationship of IO-
therapy. Januschowski et al. attached a microsensor to
common spectacles to monitor adherence [16]. This mi-
crosensor conveniently fits IO-therapy glasses; we have
tested the feasibility of the sensor in monitoring adher-
ence with IO-therapy glasses [15]. We will use this mi-
crosensor to monitor IO-therapy in this study.
Our working hypothesis is that an intense regimen of
IO-therapy (three times the standard regimen dosage)
with a shorter duration (one third of treatment duration)
would be non-inferior to the standard regimen of IO-
therapy with same cumulative amount of occlusion
hours. For treating moderate amblyopia, 12 h per day (h/
day) of IO-therapy for 4 weeks would not be inferior to
4 h/day of IO-therapy for 12 weeks. It can be simplified
with a mathematical equation, where D represents day
and WK represents weeks: 12 h/D x 4WK = 4 h/D x
12WK. To test this hypothesis, we designed a random-
ized controlled trial to compare the intense regimen
with the standard regimen of IO-therapy for treating
moderate amblyopia.
Methods/design
Objectives of the study
The primary study objective is to compare the effective-
ness of an intense regimen with the standard regimen of
IO-therapy in children ages 3 to ≤ 8 years with moderate
amblyopia. The secondary study objectives are (1) to de-
termine whether adherence differs between the intense
regimen and the standard regimen of IO-therapy and (2)
to determine the dose-response relationship in IO-
therapy.
Ethical approval and conduct
This research protocol number HJW1604 and the in-
formed consent forms were approved by the institutional
review board (IRB) of Salus University. The clinical trial
number is NCT02767856, registered on May 10, 2016
(www.clinicaltrials.gov). The Health Insurance Portabil-
ity and Accountability Act will be observed during this
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study. Informed consent will be obtained from the par-
ticipant’s parent or guardian (hereafter referred to as
“parent”) by study investigators or coordinators; assent
will also be obtained from participants 7–8 years of age.
The IRB of Salus University, including interdisciplinary
scientists, clinicians, and statisticians will monitor data
safety annually.
Recruitment sites
Four study sites in the USA will enroll potential study
participants; they are The Eye Institute of Salus Univer-
sity, Philadelphia, PA (which is also the coordinating
center); Illinois College of Optometry, Chicago, IL;
Nemours. Alfred I. DuPont Hospital of Children,
Wilmington, DE; and Arkansas Children’s Hospital, Lit-
tle Rock, AR. They are all academic hospitals or clinics.
A flyer will be used to advertise the study and the site
principal investigators (PIs) and co-investigators will
identify study participants. Participants may self-identify,
contact the investigators, and join the study. The study
has a randomized, parallel group, semi-masked design
(examiners are masked), as depicted in Fig. 1.
Eligibility testing includes measurement of visual acu-
ity in both eyes using the standard Amblyopia Treat-
ment Study single-surround HOTV letter protocol [17]
and a routine comprehensive eye exam (comprehensive
ocular examination and a full motility examination).
Cycloplegic refraction is completed within 6 months.
The eligibility inclusion criteria are:
1. Age range from 3 to < 8 years, which is similar to
the age range used in a previous Pediatric Eye
Disease Investigator Group (PEDIG) study [5].
2. Unilateral amblyopia - best-corrected visual acuity
(BCVA) of the amblyopic eye ranging from 20/40
to 20/80 [5]; interocular logMAR chart difference of
at least two lines; BCVA in the sound eye of at least
20/40 or better.
3. Amblyopia associated with strabismus,
anisometropia, or both.
4. Prior to the time of enrollment, the participant has
worn optimal spectacle correction (if needed) for a
minimum of 12 weeks or until stability of visual
acuity was documented (no improvement in
amblyopic eye visual acuity at two consecutive visits
at least 4 weeks apart). Details of the protocol for
refractive correction for moderate amblyopia
followed guidelines of a previous PEDIG study [18].
5. The amblyopic eye was untreated by either
patching or atropine for at least 6 months.
6. Gestational age > 34 weeks and birth weight > 1500 g.
7. Parents are willing to accept randomization, be
contacted, and have access to a phone.
The exclusion criteria are:
1. The amblyopic eye has myopia worse than − 3.00 D
spherical equivalent.
2. Prior intraocular or refractive surgery.
Fig. 1 Study participant flow. IO-therapy, intermittent occlusion therapy
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3. Ocular conditions that impact vision e.g. cornea
scar.
4. Cognitive impairment that prohibits accurate data
collection; Down’s syndrome or developmental
delays.
Procedure
After confirming the enrollment criteria (Fig. 2), each
participant will be randomized to one of two treatment
groups:
 Standard group: 4-h daily wearing of IO-therapy
glasses for 12 weeks
 Intense group: 12-h daily wearing of IO-therapy
glasses for 4 weeks
The randomized group number for each participant is
pre-sealed in an opaque envelope by a research assistant.
All envelopes are kept in a box in sequence. When a
participant is eligible for the study, we will have the par-
ticipant open the envelope according to the sequence. If
a participant is enrolled from a site outside of The Eye
Institute of Salus University, the coordinator calls the
central phone of the study manager, and the study man-
ager will open the envelope in the sequence and inform
the coordinator as to which group the participant has
been randomized.
After randomization, each child will be provided a pair
of IO-therapy glasses (Amblyz™ liquid crystal glasses,
XPAND 3D Group, Limassol, Cyprus). The glasses are
set at 30-s opaque/transparent intervals for the non-
amblyopic fellow eye. These glasses contain the child’s
prescription and are rechargeable overnight. It often
Fig. 2 Standard protocol items: recommendation for interventional trials (SPIRIT) figure. IO-therapy, intermittent occlusion therapy
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takes 7–14 days to prepare the child’s prescription
spectacles to be fitted with the IO-therapy glasses and
deliver them to the child.
To independently report adherence to wearing the IO-
therapy glasses, all participants will be provided with a
TheraMon microsensor (Hargelsberg, Austria) [16]. This
inexpensive, commercially available, microsensor is at-
tached to the temple arm of the IO-therapy glasses with
commercial superglue and confers no additional risk to
the wearer. Based on wearing events recorded using the
microsensor, we will evaluate adherence at the scheduled
clinic visits, data will be read and will provide a time his-
tory of episodes of wearing the IO-therapy glasses. A full
description and a picture of the IO-therapy glasses at-
tached with a microsensor and the mode of operation has
been provided previously [15, 16]. The parent will be con-
tacted by phone 1 week after initiation of the treatment,
to answer any questions and to encourage compliance
with treatment.
During the trial period, participants will not be
allowed to receive other amblyopia treatments such as
patching or atropine besides the prescribed hours of
wearing the IO-therapy glasses or their own spectacles.
Primary outcome visit (both 4 ± 1 weeks and 12 ± 1
weeks) After participants receive their glasses, the pri-
mary outcome visit will occur at 4 ± 1 weeks in the in-
tense group and at 12 ± 1 weeks in the standard group.
In addition, we ask the standard group to return at 4 ± 1
weeks for comparison with the intense Group.
Masked examiners, who do not know to which treat-
ment group the participant is randomized, will perform
both baseline and primary outcome tests. In addition to
visual acuity, stereoacuity, and ocular alignment assess-
ment, we also read microsensor data. Microsensor data
will be logged by connecting the microsensors to the read-
ing station via an antenna at a distance of 2–3 cm from
the antenna. A USB cable will transfer the data to a PC;
wearing times will be evaluated using the TheraMon® Soft-
ware and compared to the wearing times protocol. The
participant’s parent will be asked to comment on their
child’s experiences with the IO-therapy glasses.
Adverse events
We monitor for potential major adverse events to in-
clude reverse amblyopia in the non-amblyopic eye (de-
crease of 2 lines in visual acuity), significant changes in
ocular alignment (deviation changes of ≥ 10Δ), or any in-
jury associated with the IO-therapy glasses or the micro-
sensor. Any loss or possible breakage will be recorded.
Study participants who lose or break the glasses will re-
ceive a new pair and continue the study.
Sample size calculation and randomization
preparation The sample size for this study was calcu-
lated based on a standard two-sided trial with a continu-
ous outcome. The calculations assume 5% type I error
with 80% power; the standard deviation of change from
the baseline was 0.14, and the effective size difference
was 0.12. Therefore, we anticipate that we will require
46 total participants (i.e., 23 in each group) [9]. Because
the IO-therapy glasses are a novel device used to treat
severe amblyopia, we are uncertain how many 3–8 year-
old participants will drop out of the study. According to
an average 15% dropout rate in previous amblyopia stud-
ies [6, 19], we have increased the sample size to 28 in
each group to account for attrition. After collecting data
from 28 participants, we will re-estimate the sample size
based on updated attrition and standard deviation esti-
mates [20].
With an online research randomization program
(www.randomizer.org) of a permuted-block (N = 4) non-
inferiority design, 56 participants will be randomized
into the two treatment groups with 28 participants in
each group. The allocation ratio is 1:1.
Outcomes and follow up The primary outcome is the
visual acuity change from the baseline in logMAR in the
amblyopic eye as determined at the primary outcome
visit. In the standard group, the primary outcome visit is
at 12 ± 1 weeks; in the intense group, the primary out-
come visit is at 4 ± 1 weeks. The study is continued if
visual acuity in the amblyopic eye at the primary out-
come visit has improved by at least one logMAR line;
otherwise, the study is completed. We will also record
parents’ feedback about the participants’ daily life experi-
ences with the IO-therapy glasses.
If a participant meets the criteria to continue the
study, the following steps will be observed: in the intense
group, if equal vision is achieved in both eyes at the pri-
mary outcome visit, the participant will stop treatment
for 8 weeks and return for a study visit; if vision is not
equal in both eyes, treatment will continue for another
4 ± 1 weeks until there is no more improvement. In the
standard group, participants return every 12 ± 1 week
until there is no more improvement. Due to limited
funding, there will be no more than three additional
visits after the primary outcome visit in either group.
To protect participants’ confidentiality, all study-related
procedures will be conducted in a private area - office or
exam room - at a scheduled time; participant-related doc-
uments (consent forms and measurement reports) will be
locked in a file cabinet, which only approved personnel
can access. Data entry, storage, and management and
protocol modifications follow Salus IRB instructions. The
principal investigators and data analysts will access the
final dataset. The principal investigators and co-
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investigators communicate periodically on study progress,
updates, and study-relevant issues, such as protocol
decision-making, manuscript writing, and publication. We
will present at conferences and publish results. When the
study is finished, we will communicate our findings to the
parents. De-identified data tables will be shared by request
after the primary outcome data have been published. A
contact will be provided in the publication.
Adherence outcome
Adherence is defined as the percentage of hours the
glasses are actually worn compared to the prescribed
hours of wearing. Daily adherence is calculated, and gen-
eral adherence is determined as the average of daily ad-
herence in individuals. We will also evaluate the reasons
for possible low adherence.
Analysis
Once a participant is randomized, the participant will be in-
cluded in the analysis regardless of whether or not the
assigned treatment is received. That is to follow the “intent-to-
treat” design. Because the participant’s adherence is recorded
by the microsensor, we will be able to better understand the
dose-response relationship of IO-therapy through this study.
Descriptive statistics (mean and standard deviation)
will be applied to the primary and secondary outcomes.
The paired t test will be applied to analyze visual acuities
before and after treatment in each group; the independ-
ent t test will be applied to compare visual acuity im-
provement in the two groups. Confidence intervals (CIs)
for visual acuity improvement are reported in a non-
inferiority manner [21]. The upper limit of a one-sided
97.5% CI will be computed on the treatment group dif-
ference in mean change in amblyopic-eye visual acuity,
adjusting for baseline visual acuity, using analysis of co-
variance (ANCOVA).
The microsensor recording will provide data on the
number of hours the glasses are worn each day. With
total hours during treatment and improved visual acuity
in the amblyopic eye, we can estimate the dose-response
relationship for IO-therapy.
After the intervention type is considered, correlation
coefficients will be calculated for the treatment response
(improved visual acuity in the amblyopic eye) to the var-
iables that are often suggested as important factors: (1)
baseline visual acuity, (2) severity of amblyopia, and (3)
participant age [22].
Discussion
The trial protocol described herein aims to compare two
regimens of IO-therapy glasses when treating children
ages 3 to < 8 years who have unilateral amblyopia. We
anticipate that the proposed study will provide the first
data on the dose-response relationship of IO-therapy in
treating moderate amblyopia. This study is designed to
test the hypothesis: 12 h/D x 4WK = 4 h/D x 12WK.
Since visual acuity improvement in the amblyopic eye
is not linear, it is possible that 4 h/day for 4 weeks is suf-
ficient to be effective, and any additional hours are a
waste of time. That is why we have another hypothesis:
12 h/D x 4WK = 4 h/D x 4WK. Therefore, we ask the
standard group to return at 4 ± 1 weeks for comparison
with the intense group.
Although cumulative occlusion hours matter in IO-
therapy, treatment duration may also be important. Pos-
sibly the effectiveness of the intense regimen will not last
as long as that of the standard regimen. It is advisable to
add a longer follow-up period. Therefore, we need to
test hypothesis: 12 h/D x 4WK + 0 h/D x 8WK = 4 h x
12WK. Ideally, we will have participants in the intense
group return at 4 weeks and stop the treatment for 8
weeks, then return for assessment of the primary out-
come. However, because this is a pilot study on the regi-
men, our IRB has concerns about the ethical issue of
stopping treatment and requests us to continue to treat
participants if they show improvement with IO-therapy.
Therefore, in this phase, we are not able to test this hy-
pothesis. We may test it in the near future based on the
data from this project.
It is necessary to emphasize that the strength of this
study is the use of microsensors. To avoid loss of the
sensor or malfunctioning of the sensor, we advise partic-
ipants to keep the glasses in the box indoors when they
take them off.
According to the severity of amblyopia, PEDIG classi-
fied amblyopia into moderate amblyopia and severe am-
blyopia. Instead of 2 h/day of occlusion for moderate
amblyopia, the dosage of 6 h/day of occlusion is recom-
mended for severe amblyopia. In this study, we are only
studying the regimen of treatment for moderate ambly-
opia. Therefore, the relevance of the results of this study
is limited to the treatment of moderate amblyopia. In
addition, after this study, we may investigate the sustain-
ability of the IO-therapy effects in a large sample size.
Trial status
Participant enrollment commenced in May 2016. The
first participant was enrolled in October 2016, and the
trial is scheduled to be completed by December 2020.
The trial was approved on 29 April 2016. It was
amended on 27 June 2016, 29 June 2016, 13 September
2016, 27 September 2016, 15 December 2016, 17 Febru-
ary 2017, 22 February 2017, 19 April 2017 (continue re-
view approval), 20 June 2017, 13 November 2017, 19
December 2017, 5 April 2018 (continue review ap-
proval), 27 August 2018, 18 December 2018, 6 March
2019, 9 April 2019, 10 April 2019 (continue review
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approval). It was amended 15 times and review was con-
tinued 3 times.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04284-4.
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